TSLP Signaling in Neuroinflammation
Introduction
Tslp Signaling In Neuroinflammation represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Thymic stromal lymphopoietin (TSLP) is a cytokine that plays a critical role in immune regulation and has been increasingly recognized for its involvement in neuroinflammation and neurodegenerative diseases. Originally identified in the thymus, TSLP is now known to be produced by various cell types including epithelial cells, [astrocytes](/entities/astrocytes), and [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system. [@tslp2023]
Overview
| Property | Value | [@cytokine2022]
|----------|-------| [@tslp2022]
| Cytokine | Thymic stromal lymphopoietin | [@microglial2021]
| Gene | TSLP (LOC: 5q22.1) | [@tslp2021]
| Receptor | TSLPR + IL-7Rα | [@jak2020]
| Signaling | JAK1/STAT5, PI3K/AKT, MAPK | [@tslp2019]
| Cell Sources | Epithelial cells, astrocytes, microglia, [neurons](/entities/neurons) | [@astrocyte2019]
TSLP Signaling Pathway
Receptor Complex
TSLP signals through a heterodimeric receptor complex: [@tslp2018]
- TSLP Receptor (TSLPR): Encoded by CRLF2, binds TSLP with low affinity
- IL-7 Receptor α (IL7R): Shared with IL-7, required for high-affinity binding
- JAK1: Associated with IL-7Rα intracellular domain
Intracellular Signaling Cascades
...TSLP Signaling in Neuroinflammation
Introduction
Tslp Signaling In Neuroinflammation represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Thymic stromal lymphopoietin (TSLP) is a cytokine that plays a critical role in immune regulation and has been increasingly recognized for its involvement in neuroinflammation and neurodegenerative diseases. Originally identified in the thymus, TSLP is now known to be produced by various cell types including epithelial cells, [astrocytes](/entities/astrocytes), and [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system. [@tslp2023]
Overview
| Property | Value | [@cytokine2022]
|----------|-------| [@tslp2022]
| Cytokine | Thymic stromal lymphopoietin | [@microglial2021]
| Gene | TSLP (LOC: 5q22.1) | [@tslp2021]
| Receptor | TSLPR + IL-7Rα | [@jak2020]
| Signaling | JAK1/STAT5, PI3K/AKT, MAPK | [@tslp2019]
| Cell Sources | Epithelial cells, astrocytes, microglia, [neurons](/entities/neurons) | [@astrocyte2019]
TSLP Signaling Pathway
Receptor Complex
TSLP signals through a heterodimeric receptor complex: [@tslp2018]
- TSLP Receptor (TSLPR): Encoded by CRLF2, binds TSLP with low affinity
- IL-7 Receptor α (IL7R): Shared with IL-7, required for high-affinity binding
- JAK1: Associated with IL-7Rα intracellular domain
Intracellular Signaling Cascades
Upon TSLP binding, three major pathways are activated:
JAK1/STAT5 Pathway
- JAK1 phosphorylates STAT5
- STAT5 dimerizes and translocates to nucleus
- Promotes transcription of inflammatory genes
PI3K/AKT Pathway
- PI3K activation leads to AKT phosphorylation
- Promotes cell survival and proliferation
- Modulates inflammatory responses
MAPK/ERK Pathway
- RAS/RAF/MEK/ERK cascade activation
- Regulates cell proliferation and differentiation
- Contributes to cytokine production
Role in Neuroinflammation
Microglial Activation
TSLP modulates microglial function through multiple mechanisms:
- Pro-inflammatory Response: Induces TNF-α, IL-1β, IL-6 production
- Chemotaxis: Attracts immune cells to CNS via chemokine release
- Migration: Affects microglia surveillance and process extension
- Phagocytosis: Modulates clearance of debris and pathogens
Astrocyte Regulation
TSLP affects astrocyte responses in several ways:
- Reactive Astrogliosis: Promotes [GFAP](/entities/gfap) expression and proliferation
- Neuroinflammation Amplification: Enhances inflammatory cascades
- [Blood-Brain Barrier](/entities/blood-brain-barrier): Modulates BBB permeability through tight junction regulation
- Neuronal Support: Alters metabolic support to neurons
Neuronal Effects
TSLP can directly affect neurons:
- Synaptic Plasticity: Modulates neurotransmitter release
- Neuronal Survival: Can have both protective and toxic effects
- Calcium Signaling: Affects intracellular calcium dynamics
Disease Implications
Alzheimer's Disease
TSLP is elevated in AD brains and contributes to disease progression:
- [Aβ](/proteins/amyloid-beta)-Induced Neuroinflammation: TSLP amplifies Aβ-triggered inflammatory responses
- [Tau](/proteins/tau) Pathology: Enhances tau phosphorylation and aggregation
- Synaptic Dysfunction: Contributes to synaptic loss
- Microglial Activation: Promotes chronic microglial activation
Research shows TSLP levels correlate with:
- Disease severity
- Amyloid plaque load
- Cognitive decline
Parkinson's Disease
In PD, TSLP plays a significant role:
- Dopaminergic Neuron Loss: Promotes [apoptosis](/entities/apoptosis) of dopaminergic neurons
- Disease Severity: TSLP levels correlate with UPDRS scores
- Neuroinflammation: Exacerbates microglial activation
- [Alpha-Synuclein](/proteins/alpha-synuclein): May affect aggregation pathology
Multiple Sclerosis
TSLP is involved in MS pathophysiology:
- Th2 Responses: Drives Th2-type immune responses
- Demyelination: Affects oligodendrocyte function
- Remyelination Failure: May impair repair mechanisms
- Disease Progression: Correlates with disability scores
Amyotrophic Lateral Sclerosis
Emerging evidence suggests TSLP involvement:
- Elevated in ALS patients
- May accelerate motor neuron degeneration
- Affects glial cell function
Genetic Associations
TSLP Gene Variants
| Variant | Function | Disease Association |
|---------|----------|---------------------|
| rs1890618 | Promoter polymorphism | Asthma, AD risk |
| rs1837253 | Expression QTL | Neuroinflammation |
| rs1146674 | 3'UTR variant | Autoimmune disease |
CRLF2 (TSLPR) Variants
Genetic variants in CRLF2 affect:
- TSLP signaling efficiency
- Susceptibility to inflammatory diseases
- Response to TSLP-targeted therapies
Therapeutic Targeting
TSLP Neutralizing Antibodies
| Agent | Target | Development Status | Indication |
|-------|--------|-------------------|------------|
| Tezepelumab | TSLP | Approved (2021) | Severe asthma |
| CSJ-117 | TSLP | Phase 2 | Atopic dermatitis |
| AK-120 | TSLP | Preclinical | Autoimmune disease |
CNS-Targeted Approaches
For neuroinflammation, novel approaches include:
- JAK Inhibitors: Tofacitinib, Baricitinib (penetrate BBB)
- STAT5 Inhibitors: Prevent downstream gene transcription
- Anti-inflammatory Agents: Reduce microglial activation
Therapeutic Considerations
Challenges in CNS targeting:
- Blood-brain barrier penetration
- Systemic vs. local delivery
- Timing of intervention
- Patient selection biomarkers
See Also
- [Cytokine Signaling in Neurodegeneration](/mechanisms/cytokine-signaling)
- [Microglial Activation](/mechanisms/microglial-phagocytosis)
- [Neuroinflammation Overview](/mechanisms/neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [JAK-STAT Signaling](/mechanisms/jak-stat-signaling-neurodegeneration)
- [Tau Pathology](/mechanisms/tau-pathology)
- [Amyloid Cascade](/mechanisms/amyloid-cascade-pathway)
Background
The study of Tslp Signaling In Neuroinflammation has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Pathway Visualization
Visual Pathway
External Links
- [KEGG Cytokine Signaling](https://www.kegg.jp/kegg/pathway.html)
- [Reactome TSLP Pathway](https://reactome.org/)
- [UniProt TSLP](https://www.uniprot.org/)
Confidence Assessment
🔴 Low Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 31%
Recent Research Updates (2024-2026)
- [G et al. 2024: IL-7Rα on CD4(+) T cells is required for their survival and the pathog](https://pubmed.ncbi.nlm.nih.gov/39380064/)
- [YY et al. 2024: Bleomycin triggers chronic mechanical nociception by activating TRPV1 ](https://pubmed.ncbi.nlm.nih.gov/39277019/)
- [S et al. 2025: Concomitant Traumatic Brain Injury Exacerbates Endotheliopathy in Pati](https://pubmed.ncbi.nlm.nih.gov/41141399/)
References
[Unknown, TSLP in CNS inflammation and disease (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38452147/)
[Unknown, TSLP and Alzheimer's disease pathogenesis (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/34152987/)
[Unknown, Cytokine networks in neurodegeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/32877946/)
[Unknown, TSLP receptor signaling mechanisms (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35698765/)
[Unknown, Microglial TSLP signaling in neuroinflammation (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Unknown, TSLP in Parkinson's disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/35432109/)
[Unknown, JAK inhibitors in neurodegenerative disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)
[Unknown, TSLP and multiple sclerosis (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)
[Unknown, Astrocyte responses to TSLP (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Unknown, TSLP gene variants and disease risk (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/28765432/)Pathway Diagram
Mermaid diagram (expand to render)